KDM1A and cancer: Among these inhibitors, ORY-1001 and GSK2879552 have entered clinical trials, thus validating the clinical application of LSD1 as a therapeutic target for cancers and incredibly encouraging the development of strategies targeting LSD1 for treating cancers.